Few pet owners are comfortable with seeing their animals in pain, and Zoetis CEO Juan Ramon Alaix said his company's latest blockbuster drug, Apoquel, stretches the boundaries of allergic itch treatment in pets.
"It's better in terms of efficacy. It's faster," Alaix told "Mad Money" host Jim Cramer on Monday. "You don't see the side effects that you see with steroids, which is very important for pet owners and veterinarians."
Alaix said innovation led his company to release this landmark drug, which quickly swept up 47 percent of the market share in the atopic dermatitis space for dogs.
The drug is often paired with an injectable medication called Cytopoint, which uses monoclonal antibodies to produce fewer side effects.
The company's recently announced acquisition of Nexvet Biopharma, a leader in pet medications that use monoclonal antibodies, will be key to developing medicines with fewer adverse side effects and could actually forge the way to disrupting the fairly barren treatment market for cats, the CEO said.
Watch the full segment here: